The content on this site is intended for healthcare professionals only
Prof Peter Schmid presents data from the KEYNOTE-522 trial during a press conference at the 2019 ESMO congress.
This was a phase III trial looking at immunotherapy added to chemotherapy in early triple negative breast cancer.
Watch Prof Schmid's interview with ecancer here.
Read more about the study here.
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
ASCO 2024: Lung cancer highlights
ASCO 2024: Lung cancer roundup
Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
OncoAlert round up July 28th to August 3rd, 2023
Management of HER2 positive metastatic breast cancer treatment algorithm
Post neoadjuvant management in BRCA mutant breast cancer patients
NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer
